Abbott could double by 2036 on 8% earnings growth
Alpha Vantage · The Globe and Mail · · AI-summarised by FinFlash
Abbott Laboratories could more than double by 2036 if earnings compound at a conservative 8% annually, according to an analysis that cites the company's historical earnings growth, Dividend King status and high-yielding dividend. Analysts carry an average target of Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.Understand the context